A Generalized Framework for Video Instance Segmentation

The handling of long videos with complex and occluded sequences has recently emerged as a new challenge in the video instance segmentation (VIS) community. However, existing methods have limitations in addressing this challenge. We argue that the biggest bottleneck in current approaches is the discrepancy between training and inference. To effectively bridge this gap, we propose a Generalized framework for VIS, namely GenVIS, that achieves state-of-the-art performance on challenging benchmarks without designing complicated architectures or requiring extra post-processing. The key contribution of GenVIS is the learning strategy, which includes a query-based training pipeline for sequential learning with a novel target label assignment. Additionally, we introduce a memory that effectively acquires information from previous states. Thanks to the new perspective, which focuses on building relationships between separate frames or clips, GenVIS can be flexibly executed in both online and semi-online manner. We evaluate our approach on popular VIS benchmarks, achieving state-of-the-art results on YouTube-VIS 2019/2021/2022 and Occluded VIS (OVIS). Notably, we greatly outperform the state-of-the-art on the long VIS benchmark (OVIS), improving 5.6 AP with ResNet-50 backbone. Code is available at https://github.com/miranheo/GenVIS.Comment: CVPR 202

Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification.

UNLABELLED: Hepatic resection is the most curative treatment option for early-stage hepatocellular carcinoma, but is associated with a high recurrence rate, which exceeds 50% at 5 years after surgery. Understanding the genetic basis of hepatocellular carcinoma at surgically curable stages may enable the identification of new molecular biomarkers that accurately identify patients in need of additional early therapeutic interventions. Whole exome sequencing and copy number analysis was performed on 231 hepatocellular carcinomas (72% with hepatitis B viral infection) that were classified as early-stage hepatocellular carcinomas, candidates for surgical resection. Recurrent mutations were validated by Sanger sequencing. Unsupervised genomic analyses identified an association between specific genetic aberrations and postoperative clinical outcomes. Recurrent somatic mutations were identified in nine genes, including TP53, CTNNB1, AXIN1, RPS6KA3, and RB1. Recurrent homozygous deletions in FAM123A, RB1, and CDKN2A, and high-copy amplifications in MYC, RSPO2, CCND1, and FGF19 were detected. Pathway analyses of these genes revealed aberrations in the p53, Wnt, PIK3/Ras, cell cycle, and chromatin remodeling pathways. RB1 mutations were significantly associated with cancer-specific and recurrence-free survival after resection (multivariate P = 0.038 and P = 0.012, respectively). FGF19 amplifications, known to activate Wnt signaling, were mutually exclusive with CTNNB1 and AXIN1 mutations, and significantly associated with cirrhosis (P = 0.017). CONCLUSION: RB1 mutations can be used as a prognostic molecular biomarker for resectable hepatocellular carcinoma. Further study is required to investigate the potential role of FGF19 amplification in driving hepatocarcinogenesis in patients with liver cirrhosis and to investigate the potential of anti-FGF19 treatment in these patients. (Hepatology 2014;60:1971-1981). Hepatology 2014 Dec; 60(6):1972-82